✦ LIBER ✦

Novozymes 1Q 2010: strong performance and increased expectations

Publisher: Elsevier Science
Year: 2010
Weight: 63 KB
Volume: 2010
Category: Article
ISSN: 1351-4210
DOI: 10.1016/s1351-4210(10)70215-8

No coin nor oath required. For personal study only.

✦ Synopsis

net sales of €245 M (€209 M for its 1Q 2009) and recurring EBITDA of €38 M (€14 M). Novecare reported significant improvement in profit driven by increased activity (volumes up by 18% year-on-year) across all regions, particularly in Asia. Volumes in the Industrial and the Agrochemical markets enjoyed a strong recovery. The Oilfield chemicals business is progressively recovering quarter after quarter. In 2Q 2010, Novecare should continue to deliver good performance.

📜 SIMILAR VOLUMES

Novozymes 1Q 2010: strong 1Q 2010 perfor

Novozymes 1Q 2010: strong 1Q 2010 performance and increased expectations for full year 2010

📂 Article 📅 2010 🏛 Elsevier Science ⚖ 59 KB

## LS9 to produce biodiesel in Florida LS9, a renewable petroleum company, will revamp an existing fermentation plant in Okeechobee, FL, to allow production of its UltraClean Diesel and chemicals, initially at a demonstration scale, for ramp up to commercial scale. The plant, which the company rece

Novozymes Inc increases 2010 expectation

Novozymes Inc increases 2010 expectations after strong 1H 2010 performance

📂 Article 📅 2010 🏛 Elsevier Science ⚖ 52 KB

Novozymes Jan-Sep 2010: increased full-y

Novozymes Jan-Sep 2010: increased full-year 2010 expectations after strong 9 month sales and earnings performance

📂 Article 📅 2010 🏛 Elsevier Science ⚖ 53 KB

## Lummus-BP license deal BP has granted Lummus Technology the exclusive licensing and marketing rights to its paraxylene recovery and isomerization process and catalysts. Lummus will handle all sales, marketing and licensing activities.

Novozymes Inc reports strong 3Q 2010 per

Novozymes Inc reports strong 3Q 2010 performance

📂 Article 📅 2011 🏛 Elsevier Science ⚖ 50 KB

Strong sales and margin growth for Novoz

Strong sales and margin growth for Novozymes in 1Q 2006

📂 Article 📅 2006 🏛 Elsevier Science ⚖ 50 KB

also rejected the latest offer of $38 per share. BASF is "considering all its options." Engelhard is also to increase the size of its board from six to nine members.